NewAmsterdam Pharma Set for Key Presentations and Events in September
NewAmsterdam Pharma's Upcoming Events and Presentations
NAARDEN and MIAMI — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a leader in biopharmaceutical innovations, is gearing up for a series of significant events in the coming weeks. This late-stage clinical biopharmaceutical firm is dedicated to developing oral, non-statin medications aimed at patients facing cardiovascular disease (CVD) risks due to elevated low-density lipoprotein cholesterol (LDL-C). Unfortunately, current treatment options often fall short for these individuals. To address this, NewAmsterdam will share pivotal findings on their investigational treatments at key industry gatherings.
European Society of Cardiology Congress
This year, NewAmsterdam will present at the esteemed European Society of Cardiology Congress (ESC), scheduled from August 29 to September 1. This Congress serves as a prominent platform for cardiology professionals worldwide, offering insights into cutting-edge research and treatments. NewAmsterdam will highlight pooled safety and efficacy data from the Phase 3 BROADWAY and BROOKLYN trials.
Presentation Details
One of the key presentations will be on the efficacy of obicetrapib across various lipid-lowering therapies based on the Broadway and Brooklyn randomized trials. Dr. Kausik Ray will present this enlightening session titled "Changing Face of Lipid-Lowering Therapy" on August 29 at 10:10 AM CEST. Additionally, Dr. Stephen Nicholls will discuss the impact of obicetrapib on cardiovascular events during the "Late-Breaking Clinical Science" session on September 1 at 9:00 AM CEST.
Participation in Investor Conferences
Aside from the ESC, NewAmsterdam will also engage actively in several crucial investor conferences during the same time frame. One highlighted event is Citi's 2025 Biopharma Back to School Summit on September 3, where CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at 2:30 PM ET in Boston.
Other Notable Conferences
NewAmsterdam will continue its conference schedule with the Cantor Global Healthcare Conference on September 4, presenting again with Dr. Davidson and Mr. Somaiya at 2:45 PM ET in New York. Finally, the company will conclude their participation in this series with the Wells Fargo Healthcare Conference on September 5, showcasing insights from CFO Ian Somaiya at 10:15 AM ET in Boston.
Webcast Availability
For those unable to attend, live webcasts of these presentations will be accessible via the investor relations section of the NewAmsterdam Pharma website. Following these live events, recorded sessions will also be made available for later viewing, ensuring that stakeholders stay informed of the latest developments.
About NewAmsterdam Pharma
NewAmsterdam Pharma (Nasdaq: NAMS) is committed to enhancing patient outcomes for metabolic diseases, particularly in populations with unmet medical needs. The company is focused on ensuring patients have access to safe and effective therapies that significantly lower LDL levels while being well-tolerated. NewAmsterdam is striving to broaden the therapeutic options by utilizing obicetrapib—a once-daily CETP inhibitor—to enhance LDL-C reduction, especially in patients already on statin therapies who are often underserved by existing treatments.
Company Contact Information
Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com
Frequently Asked Questions
What is the purpose of NewAmsterdam Pharma's upcoming presentations?
The presentations aim to showcase new data from their clinical trials on LDL-C treatments, which could significantly impact cardiology practices.
When and where will the European Society of Cardiology Congress take place?
The Congress is set for August 29 to September 1 in Madrid, serving as a significant platform for health professionals in cardiology.
Who will represent NewAmsterdam Pharma at the investor conferences?
CEO Michael Davidson and CFO Ian Somaiya will be key presenters at multiple investor events, engaging with industry stakeholders.
Will the presentations be available for later viewing?
Yes, live webcasts will be provided and recordings will be accessible for those who cannot attend the live sessions.
What is NewAmsterdam Pharma's core mission?
The company aims to innovate safe and effective treatments for metabolic diseases, particularly for patients at risk of cardiovascular complications.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
